Higher Than Expected Clozapine Serum Level and Clozapine/Norclozapine Ratio Due to Cyp450 Gene Polymorphisms
Authors:
- 6 November 2015
- journal article
- Published by Taylor & Francis in Personalized Medicine
- Vol. 12 (6) , 555-558
Abstract
Aims: We investigated a case of the unexpectedly high clozapine/norclozapine serum levels in a non-smoker, female patient. Method: The RFLP genotype method was used for the loss-of-function CYP450 gene polymorphisms detection. Results: The genotype revealed the presence of CYP2D6*41/*41, rs28371725, NM_000106.5:c.985+39G>A and CYP1A2*1/*1D rs35694136, NM_000761.4:c.-1635delT. Conclusion: An appropriate clozapine serum level is required for both optimization of clinical response and avoidance of troublesome, or even life-threatening side effects. Although not the only factor, genetic polymorphisms responsible for the metabolism of clozapine play an important role towards such goals. Pharmacogenetic tests can guide dose adjustment in order to obtain an optimum serum level, which can lead to a better therapeutic response and minimization of harmful side effects.Keywords
This publication has 27 references indexed in Scilit:
- Use of anticonvulsants as prophylaxis for seizures in patients on clozapineAustralasian Psychiatry, 2013
- Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of DextromethorphanClinical Pharmacology & Therapeutics, 2010
- Cytochrome P450 Loss-Of-Function Polymorphism Genotyping on the Agilent Bioanalyzer and Clinical ApplicationPharmacogenomics, 2009
- Evaluating the association between clozapine and venous thromboembolismAmerican Journal of Health-System Pharmacy, 2008
- Clozapine-Associated MyocarditisDrug Safety, 2007
- Prevalence of the Metabolic Syndrome Among Patients Receiving ClozapineAmerican Journal of Psychiatry, 2006
- A double‐blind, placebo‐controlled trial of sibutramine for clozapine‐associated weight gainActa Psychiatrica Scandinavica, 2006
- Rechallenge with clozapine following leucopenia or neutropenia during previous therapyThe British Journal of Psychiatry, 2006
- Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and MortalityThe Journal of Clinical Psychiatry, 2005
- Diabetes Mellitus Among Outpatients Receiving ClozapineThe Journal of Clinical Psychiatry, 2005